AI sell-off deepens as chip stocks slump in market retreat - business live
Pharmaceutical giant GSK is relocating its main R&D hub from Stevenage to a new facility in Cambridge by 2029 as part of a £400 million investment. The move is expected to integrate the company into the Cambridge Biomedical Campus while prompting internal restructuring and potential job cuts.
Why it matters
This investment highlights the UK's strategic focus on life sciences and medical innovation, though it raises concerns regarding regional employment shifts.
GSK mock-up of new R&D centre under development in Cambridge Illustration: GSK GSK has announced it will shut its main research and development hub in Stevenage and open a new site in Cambridge.
The pharmaceutical giant said there will be a phased move more than 1,000 staff that work in Stevenage to the new 300,000 sq ft centre in Cambridge by 2029.
Some staff currently based in Stevenage will move to its site in Ware, which is also set for an upgrade as part of its £400m investment plan over the next three years.
The company, which is headquartered in London, is expected to announce sweeping cuts and redundancies across other departments to help pay for the investment.
double quotation mark This investment will accelerate our R&D and help us deliver new, competitive products.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in